“In vitro” and in Animal Model Studies on a Double Virus- Inactivated Factor VIII Concentrate

Summary

To improve the safety of plasma derived factor VIII (FVIII) concentrate, we introduced a final super heat treatment (100° C for 30 min) as additional virus inactivation step applied to a lyophilized, highly purified FVIII concentrate (100 IU/mg of proteins) already virus inactivated using the solvent/detergent (SID) method during the manufacturing process.

The efficiency of the super heat treatment was demonstrated in inactivating two non-lipid enveloped viruses (Hepatitis A virus and Poliovirus 1). The loss of FVIII procoagulant activity during the super heat treatment was of about 15%, estimated both by clotting and chromogenic assays. No substantial changes were observed in physical, biochemical and immunological characteristics of the heat treated FVIII concentrate in comparison with those of the FVIII before heat treatment.

• References

• 1 Peerlink K, Vermylen J. Acute Hepatitis A in patients with haemophilia A. Lancet 1993; 341: 179
• 2 Mannucci PM, Gdovin S, Gringeri A, Colombo M, Mele A, Schinaia N, Ciavarella N, Emerson SU, Purcell RH. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. Ann Intern Med 1994; 120 (01) 1-7
• 3 Morfini M, Mannucci PM, Ciavarella N, Schiavoni M. Prevalence of infection with the Hepatitis C virus among Italian hemophiliacs before and after the introduction of virally inactivated clotting factor concentrates: a retrospective evaluation. Vox Sang 1994; 67: 178-182
• 4 Ingerslev J. Safety of plasma derivatives. Haemostasis 1994; 24: 311-323
• 5 Horowitz B, Wiebe ME, Lippin A, Stryker MH. Inactivation of viruses in labile blood derivatives I. Disruption of lipid enveloped viruses by tri(N- butyl) phosphate detergent combinations. Transfusion 1985; 25: 516-522
• 6 Horowitz MS, Rooks C, Horowitz B, Hilgartner M. Virus safety of solvent/detergent-treated antihaemophilic factor concentrate. Lancet 1988; 2: 186-189
• 7 Schimpf K, Brackmann HH, Kreuz W, Kraus B, Haschke F, Scftritmm W, Moessler J, Auerswald G, Sutor AH, Koehler K, Hellstern P, Muntean W, Scharrer I. Absence of antihuman immunodeficiency virus types 1 and 2 seroconversion after treatment with hemophilia A and B or von Wille-brand’s disease with pasteurized factor concentrate. N Engl J Med 1989; 321: 1148-1152
• 8 Mannucci PM, Schimpf K, Brettler DB, Ciavarella N, Colombo M, Haschke F, Lechner K, Lusher J, Weissbach G. the International Study Group. Low risk for Hepatitis in hemophiliacs given a high purity, pasteurized factor VIII concentrate Ann Intern Med 1990; 113: 27-32
• 9 Shulman S, Lindgren A-Ch, Petrini P, Allander T. Transmission of Hepatitis C with pasteurized factor VIII. Lancet 1992; 340: 306-307
• 10 Skidmore SJ, Pasi KJ, Mawson SJ, Williams MD, Hill FG H. Serological evidence that dry heating of clotting factor concentrates prevents transmission of non-A, non-U Hepatitis. J Med Virol 1990; 30: 50-52
• 11 Rizza CR, Fletcher ML, Kernoff PBA. Confirmation of viral safety of dry heated factor VIII concentrate (8Y) prepared by Bio Products Laboratory: A report on behalf of UK Haemophilia Centre Directors. Br J Haematol 1993; 84: 269-272
• 12 Mariani G, Di Paoloantonio T, Baklaya R, Morfini M, Mannucci PM. Ad Hoc Study Group of the Fondazione Dell’Emofilia. Prospective study of the evaluation of Hepatitis C virus infectivity in a high purity, solvent/ detergent-treated factor VIII concentrate: Parallel evaluation of other markers for lipid-enveloped and non-lipid-enveloped viruses Transfusion 1993; 33: 814-818
• 13 Gomperts ED. Procedures for the inactivation of viruses in clotting factor concentrates. Am J Hematol 1986; 23: 295-305
• 14 Prince AM, Horowitz MS, Zang E. The development of virus-free labile blood derivatives. Eur J Epidemiol 1987; 3: 103-118
• 15 Bartolomei CorsiO, Azzi A, Morfini M, Fauci R, Rossi Ferrini P. Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrate. J Med Virol 1988; 25: 165-170
• 16 Lyon DJ, Chapman CS, Martin C, Brown KE, Clewley JP, Flower AJ, Mitchell VE. Symptomatic parvovirus B19 infection and heat-treated factor IX concentrate. Lancet 1989; 1: 1085
• 17 Azzi A, Ciappi S, Zakvzeswska K, Morfini M, Mariani G, Mannucci PM. Human parvovirus B19 infection in hemophiliacs first infused with two high-purity virally attenuated factor VIII concentrates. J Hematol 1992; 39: 228-230
• 18 Grobe-Bley A, Eis-Hübinger AM, Kaiser R, Oldenburg J, Brackmann HH, Schwarz TF, Schneweis KE. Serological and virological markers of human parvovirus B19 infection in sera of hemophiliacs. Thromb Haemost 1994; 72: 503-507
• 19 Morfini M. In vitro characteristics of highly purified factor VIII concentrates. Ann Hemat 1991; 63: 123-125
• 20 Mannucci PM. Modern treatment of hemophilia: from the shadows towards the light. Thromb Haemost 1993; 70: 17-23
• 21 Rubinstein AI, Rubinstein DB, Coughlin J. Combined solvent-detergent and 100° C (boiling) sterilizing dry-heat treatment of factor VIII concentrates to assure sterility. Vox Sang 1991; 60: 60
• 22 Franco E, Divizia M, De Santis ME, Arrighi S, Borri MG. Inattivazione tramite calore secco del Poliovirus 1 in campioni di fattore VIII. 35th National Congress of Italian Society of Hygene (Std), Montecatini Terme. Italy: 1992: 180-183
• 23 Jansen RW, Siegl G, Lemon SM. Molecular epidemiology of human Hepatitis A virus defined by an antigen-capture polymerase chain reaction method. Proe Natl Acad Sci USA 1990; 87: 2867-2871
• 24 Morace G, Pisani G, Divizia M, Paná A. Detection of Hepatitis A virus in concentrated river water by Polymerase chain reaction. Zentralblatt für Hygiene und Umweltmedizin 1993; 193: 521-527
• 25 Bowie EJ W, Thompson JH, Didishcim P, Owen CA. Mayo Clinical Laboratory Manual of Hemostasis. Philadelphia: WB Saunders; 1971
• 26 Hubbard AR, Curtis AD, Barrowelilfe TV, Edwards SJ, Jennings CA, Kemball-Cook G. Assay of factor VIII concentrates: comparison of the chromogenic and two stage clotting assay. Thromb Res 1986; 44: 887-891
• 27 Laemmli UK. Cleavage of structural proteins during the assembly of the bacteriophage T4. Nature 1970; 227: 680-685
• 28 Ouchterlony O. Diffusion in gel methods for immunological analysis. Progr Allergy. 1958 5. 1
• 29 Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrilamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci 1970; 76: 1350-1354
• 30 Grabar P, Williams CA. Métode permettante l’etude conjugée des propriété électrophoréiques et immunochimiqués d’une mélange de proteines: application au sérum sanguin. Biochim Biophys Acta (Amst) 1953; 10: 193
• 31 Cunningham AJ, Szenberg A. Further improvements in the plaque technique for detecting single antibody-forming cells. Immunology 1968; 14: 599-601
• 32 Nencioni L, Villa L, Tagliabue A, Antoni G, Presentini R, Perin F, Silvestri S, Boraschi D. In vivo immunostimulating activity of the 163-171 peptide of human IL-1ß. J Immunol 1987; 139: 800-804
• 33 Voller A, Bartlett A, Bidwell DE. Enzyme immunoassay with special reference to ELISA tecniques. J Clin Pathol 1978; 31: 507-520
• 34 Sanchez-Cuenca JM, Carmona E, Villanueva MJ, Aznar JA. Immunological characterization of factor VIII inhibitors by a sensitive micro-ELISA method. Thromb Res 1990; 57: 897-908
• 35 Di Napoli G, Bucci E. Human parvovirus B19 after concentrates for haemophilia. Lancet 1994; 343: 1566
• 36 Guillaume T. Parvovirus B19 and blood products. Lancet 1994; 343: 1101